DESTINY-PANTUMOUR04

计划入组 100 人 · 首次发布于 2025 年 8 月 15 日

DESTINY TRIAL (Inspiron x Biomatrix)

计划入组 170 人 · 首次发布于 2013 年 5 月 17 日

Diabetes Management Among Women Using an AID System: a Mixed Method Study

计划入组 69 人 · 首次发布于 2026 年 7 月 10 日

Tocilizumab biosimilar (Shanghai Destiny)

Restin

alpha-human Dectin-1-Pam3 conjugate

DESTINY PHARMA PLC

United Kingdom

Marco Kesting

Germany

CREATIVE TESTING SOLUTIONS

United States

Phase 3 DESTINY-Breast05 Trial Compares Trastuzumab Deruxtecan to T-DM1 in High-Risk HER2+ Early Breast Cancer

Enhertu Cuts Progression Risk 37% in First-Line HER2-Mutant NSCLC, Delivering 14.3-Month Median PFS in DESTINY-Lung04

DESTINY-Ovarian01 Phase 3 Trial Launches to Test ENHERTU as First-Line Maintenance Therapy for HER2-Expressing Ovarian Cancer